Literature DB >> 30658112

Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line.

Atieh Pourbagheri-Sigaroodi1, Davood Bashash2, Ava Safaroghli-Azar3, Masoumeh Farshi-Paraasghari3, Majid Momeny4, Fahimeh Nemati Mansoor1, Seyed H Ghaffari5.   

Abstract

Telomerase-mediated immortalization and proliferation of tumor cells is a promising anti-cancer treatment strategy and development of potent telomerase inhibitors is believed to open new window of treatments in human malignancies. In the present study, we found that BIBR1532, a small molecule inhibitor of human telomerase, exerted cytotoxic effects on a panel of human cancer cells spanning from solid tumors to hematologic malignancies; however, as compared with solid tumors, leukemic cells were more sensitive to this inhibitor. This was independent of molecular status of p53 in the leukemic cells. The results of a miRNA PCR array revealed that BIBR1532-induced cytotoxic effects in NB4, the most sensitive cell line, was coupled with alteration in a substantial number of cancer-related miRNAs. Interestingly, most of these miRNAs were found to act as tumor suppressors with validated targets in cell cycle or nuclear factor (NF)-κB-mediated apoptosis. In accordance with a bioinformatics analysis, our experimental studies showed that BIBR1532-induced apoptosis is mediated, at least partly, by inhibition of NF-κB. Moreover, we found that the alteration in the expression of miRNAs was coupled with the alteration in the cell cycle progression. To sum up with, a straightforward interpretation of our results is that telomerase inhibition using BIBR1532 not only induced CDKN1A-mediated G1 arrest in NB4, but also resulted in a caspase-3-dependent apoptotic cell death mostly through suppression of NF-κB axis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BIBR1532; Leukemia; MicroRNA; NF-κB; Telomerase

Mesh:

Substances:

Year:  2019        PMID: 30658112     DOI: 10.1016/j.ejphar.2019.01.018

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.

Authors:  Jixuan Gao; Hilda A Pickett
Journal:  Nat Rev Cancer       Date:  2022-07-05       Impact factor: 69.800

Review 2.  Mechanism of Human Telomerase Reverse Transcriptase (hTERT) Regulation and Clinical Impacts in Leukemia.

Authors:  Mot Yee Yik; Adam Azlan; Yaashini Rajasegaran; Aliaa Rosli; Narazah Mohd Yusoff; Emmanuel Jairaj Moses
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

3.  Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients.

Authors:  Shaian Tavakolian; Hossein Goudarzi; Ebrahim Faghihloo
Journal:  BMC Res Notes       Date:  2020-04-19

Review 4.  Advances in Pediatric Acute Promyelocytic Leukemia.

Authors:  Shannon E Conneely; Alexandra M Stevens
Journal:  Children (Basel)       Date:  2020-02-02

5.  The Small Molecule BIBR1532 Exerts Potential Anti-cancer Activities in Preclinical Models of Feline Oral Squamous Cell Carcinoma Through Inhibition of Telomerase Activity and Down-Regulation of TERT.

Authors:  Gennaro Altamura; Barbara Degli Uberti; Giorgio Galiero; Giovanna De Luca; Karen Power; Luca Licenziato; Paola Maiolino; Giuseppe Borzacchiello
Journal:  Front Vet Sci       Date:  2021-01-20

6.  Clinical Value of Serum miRNA in Patients with Acute Promyelocytic Leukemia.

Authors:  Bei Zhang; Zhixin Pei; Hongxia Wang; Junjun Bai; Junjie Wang; Yingxin Zhao; Mei Jiang; Huimin Wu; Qinglin Song
Journal:  J Oncol       Date:  2022-04-01       Impact factor: 4.375

7.  Circulating miR-148b-3p and miR-27a-3p can be potential biomarkers for diagnosis of pre-diabetes and type 2 diabetes: integrating experimental and in-silico approaches.

Authors:  Elnaz Ghoreishi; Seyedeh Zahra Shahrokhi; Faranak Kazerouni; Ali Rahimipour
Journal:  BMC Endocr Disord       Date:  2022-08-17       Impact factor: 3.263

8.  CRISPR/Cas9-Mediated TERT Disruption in Cancer Cells.

Authors:  Luan Wen; Changzhi Zhao; Jun Song; Linyuan Ma; Jinxue Ruan; Xiaofeng Xia; Y Eugene Chen; Jifeng Zhang; Peter X Ma; Jie Xu
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.